Synonyms: BTRX-246040 [1] | compound 36 [PMID: 24678969] | LY-2940094
Compound class:
Synthetic organic
Comment: LY2940094 is a potent and selective nociceptin receptor antagonist [4], with potential clinical utility as a treatment for neurobehavioral disorders [3,6].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
LY2940094 has completed Phase 2 clinical trials in major depressive disorder, in alcohol dependent subjects and in patients with Parkinson's disease. Preclinical findings are reported in [5], and proof-of-concept in alcohol dependency in [2]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01724112 | Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD) | Phase 2 Interventional | BlackThorn Therapeutics, Inc. | ||
NCT01798303 | A Study of LY2940094 in Participants With Alcohol Dependency | Phase 2 Interventional | BlackThorn Therapeutics, Inc. | ||
NCT03608371 | BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations | Phase 2 Interventional | BlackThorn Therapeutics, Inc. | ||
NCT03193398 | BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder | Phase 2 Interventional | BlackThorn Therapeutics, Inc. |